Alnylam Pharmaceuticals
ALNY
#640
Rank
$31.30 B
Marketcap
$242.68
Share price
-5.90%
Change (1 day)
42.76%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : $1.30 Billion USD

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is $1.30 Billion USD. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31$1.30 B-1.13%
2022-12-31$1.32 B32.34%
2021-12-31$0.99 B91.41%
2020-12-31$0.52 B71.54%
2019-12-31$0.30 B912.74%
2018-12-31$30 M0%
2017-12-31$30 M-80%
2016-12-31$0.15 B
2007-12-31$6.75 M-26.03%
2006-12-31$9.13 M23.54%
2005-12-31$7.39 M2.69%
2004-12-31$7.2 M287.36%
2003-12-31$1.85 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
$0.11 B-90.93%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.70 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$1.39 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.26 B-79.30%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.67 M-99.95%๐Ÿ‡บ๐Ÿ‡ธ USA
$32.15 B 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$25.46 B 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
$19.27 B 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel